Skip to main content
0151 350 1590
Back to news

EMS Healthcare appoints visionary Medical Directors onto Medical Advisory Committee

EMS Healthcare creates Medical Advisory Committee, appointing two visionary Medical Directors. This marks the establishment of EMS Healthcare’s Medical Advisory Committee, who will bring new medical perspectives, knowledge and experience to support our vision and mission. 

Dr Clare Grace Dr Clare Grace

Published 27 June 2024

EMS Healthcare appoints visionary Medical Directors onto Medical Advisory Committee Press release

We are thrilled to announce EMS Healthcare’s appointment of two distinguished Medical Directors, Professor Martin Gibson and Mr Robert Jones.

Professor Martin Gibson. MD PhD FRCP

  • A prolific career spanning over 30 years
  • A renowned clinical research physician specialising in Diabetes, Endocrinology, Lipid Disorders, Clinical Trials, Clinical Data Systems and NASH/MASH
  • Over 163 publications and 26,801 citations
  • 10+ years’ as Director of the Greater Manchester NIHR Clinical Research Network (CRN)
  • 26+ years as Consultant Physician at Salford Royal NHS Foundation Trust

Mr Robert Jones, BSc, MBChB, PhD in Cancer Pharmacology, FRCS

  • A Liver Surgeon and Honorary Associate Professor at the University of Liverpool, specialising in diseases of the gallbladder and liver
  • Research interests include oncology and vaccines, including personalised cancer vaccines
  • UK Surgical Specialty Lead in Colorectal Liver Metastases and the UK Chief Investigator for the UK’s first mRNA cancer vaccine study looking at personalised vaccine treatments for patients with resected colorectal cancer
  • A member of the NCRI Upper GI and Advanced Colorectal Cancer clinical studies group
  • Principal Investigator for 6 open and recruiting clinical studies
  • Over 186 publications and 3,231 citations

Dr Clare Grace, CEO, EMS Healthcare said, "We are delighted to welcome Martin and Robert to EMS Healthcare. Both join us with extensive experience in the development of new care pathways and significant experience in clinical drug development, and we are privileged to have them working with us.”